Tricyclics and newer antidepressant medications: Treatment options for treatment‐resistant depressions

Michael E. Thase, A. John Rush, Siegfried Kasper, Charles B. Nemeroff

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Only about 60-70% of those depressed patients who can tolerate an antidepressant medication, and only about 50-60% of those who begin a medication will respond to the first trial. Furthermore, 5-10% will remain depressed despite multiple medication trials. When the disorder is poorly responsive, it is variously described as a resistant, refractory, or intractable depression. This review summarizes the available literature on treatment-resistant depression (TRD) to provide recommendations for the most rational alternative strategies.

Original languageEnglish (US)
Pages (from-to)152-168
Number of pages17
Issue number3
StatePublished - Jan 1 1994
Externally publishedYes


  • Augmentation strategies
  • Heterocyclic antidepressants
  • Monoamine oxidase inhibitors
  • Selective serotonin reuptake inhibitors
  • Treatment-resistant depression
  • Tricyclic antidepressants

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Tricyclics and newer antidepressant medications: Treatment options for treatment‐resistant depressions'. Together they form a unique fingerprint.

Cite this